Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin
Tóm tắt
Cisplatin has been widely used to treat head and neck cancer. One of the clinical limitations with this treatment, however, is that tumors that are initially responsive to cisplatin later acquire resistance. We have recently shown that a subset of head and neck cancer cell lines has a defective Fanconi anemia DNA damage response pathway and this defect correlates to cisplatin sensitivity. We have also shown that the histone deacetylase inhibitor phenylbutyrate sensitize human cells to cisplatin. In this study we explored whether phenylbutyrate may sensitize head and neck cancer cells by interfering with the Fanconi anemia pathway. We found that the phenylbutyrate sensitizes head and neck cancer cell lines to cisplatin. This sensitization by phenylbutyrate correlated to a significant decrease in the formation of cisplatin-induced FANCD2 nuclear foci, which is a functional read out of the Fanconi anemia and BRCA (FA/BRCA) pathway. This abrogation of the FA/BRCA pathway by phenylbutyrate was not due to loss of FANCD2 monoubiquitylation but rather correlated to a phenylbutyrate-mediated reduction in the expression of the BRCA1 protein. Furthermore, we found that cancer cells defective in the FA pathway were also sensitized to cisplatin by phenylbutyrate suggesting that phenylbutyrate targets additional pathways. The results from this study suggest that phenylbutyrate may have therapeutic utility as a cisplatin sensitizer in head and neck cancer by inhibiting the FA/BRCA pathway through the down regulation of BRCA1 as well as by an FA/BRCA-independent mechanism.
Tài liệu tham khảo
Boulikas T, Vougiouka M: Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs. Oncol Rep. 2004, 11: 559-595.
Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007, 7: 573-584. 10.1038/nrc2167.
Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, Mok SC, D'Andrea AD: Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med. 2003, 9: 568-574. 10.1038/nm852.
D'Andrea AD, Grompe M: The Fanconi anaemia BRCA pathway. Nat Rev Cancer. 2003, 3: 23-34. 10.1038/nrc970.
Mirchandani KD, D'Andrea AD: The Fanconi anemia/BRCA pathway: A coordinator of cross-link repair. Exp Cell Res. 2006, 312: 2647-2653. 10.1016/j.yexcr.2006.06.014.
Burkitt K, Ljungman M: Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines. Cancer Lett. 2007, 253: 131-137. 10.1016/j.canlet.2007.01.017.
Friedberg E, Walker G, Siede W, Wood R, Schultz R, Ellenberger T: DNA Repair and Mutagenesis. 2006, Washington, D.C.: ASM Press, Second
Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003, 22: 7265-7279. 10.1038/sj.onc.1206933.
Wang D, Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005, 4: 307-320. 10.1038/nrd1691.
McHugh PJ, Sarkar S: DNA Interstrand Cross-Link Repair in the Cell Cycle: A Critical Role for Polymerase zeta in G(1) Phase. Cell Cycle. 2006, 5: 1044-1047.
Albertella MR, Green CM, Lehmann AR, O'Connor MJ: A role for polymerase eta in the cellular tolerance to cisplatin-induced damage. Cancer Res. 2005, 65: 9799-9806. 10.1158/0008-5472.CAN-05-1095.
Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, Hartman AR, Kennedy R, Foster R, Mahoney J, Seiden MV, D'Andrea AD: Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther. 2006, 5: 952-961. 10.1158/1535-7163.MCT-05-0493.
Moynahan ME, Cui TY, Jasin M: Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res. 2001, 61: 4842-4850.
Chung DH, Zhang FF, Chen F, McLaughlin WP, Ljungman M: Butyrate attenuates BCLXL expression in human fibroblasts and acts in synergy with ionizing radiation to induce apoptosis. Radiat Res. 1998, 149: 187-194. 10.2307/3579929.
Witzig TE, Timm M, Stenson M, Svingen PA, Kaufmann SH: Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents. Clin Cancer Res. 2000, 6: 681-692.
Goh M, Chen F, Paulsen MT, Yeager AM, Dyer ES, Ljungman M: Phenylbutyrate attenuates the expression of Bcl-X-L, DNA-PK, caveolin-1, and VEGF in prostate cancer cells. Neoplasia. 2001, 3: 331-338. 10.1038/sj.neo.7900165.
Batshaw ML, MacArthur RB, Tuchman M: Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr. 2001, 138: S46-54. 10.1067/mpd.2001.111836. discussion S54–45.
Resar LMS, Segal JB, Fitzpatric LK, Friedmann A, Brusilow SW, Dover GJ: Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low-dose oral sodium phenylbutyrate therapy. J Pediat Hem Onc. 2002, 24: 737-741. 10.1097/00043426-200212000-00011.
Rubenstein RC, Zeitlin PL: A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in Delta F508-homozygous cystic fibrosis patients: Partial restoration of nasal epithelial CFTR function. Amer J Respir Crit Care Med. 1998, 157: 484-490.
Monneret C: Histone deacetylase inhibitors. Eur J Med Chem. 2005, 40: 1-13. 10.1016/j.ejmech.2004.10.001.
Dyer ES, Paulsen MT, Markwart SM, Goh M, Livant DL, Ljungman M: Phenylbutyrate inhibits the invasive properties of prostate and breast cancer cell lines in the sea urchin embryo basement membrane invasion assay. Int J Cancer. 2002, 101: 496-499. 10.1002/ijc.10609.
Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, Grompe M, D'Andrea AD: Interaction of the fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell. 2001, 7: 249-262. 10.1016/S1097-2765(01)00173-3.
Vandenberg CJ, Gergely F, Ong CY, Pace P, Mallery DL, Hiom K, Patel KJ: BRCA1-independent ubiquitination of FANCD2. Mol Cell. 2003, 12: 247-254. 10.1016/S1097-2765(03)00281-8.
Bradford CR, Zhu S, Ogawa H, Ogawa T, Ubell M, Narayan A, Johnson G, Wolf GT, Fisher SG, Carey TE: P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck. 2003, 25: 654-661. 10.1002/hed.10274.
Petrie K, Prodromou N, Zelent A: Histone deacetylase inhibitors in APL and beyond. Curr Top Microbiol Immunol. 2007, 313: 157-203.
Bolden JE, Peart MJ, Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006, 5: 769-784. 10.1038/nrd2133.
Huang TT, D'Andrea AD: Regulation of DNA repair by ubiquitylation. Nat Rev Mol Cell Biol. 2006, 7: 323-334. 10.1038/nrm1908.
Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML, Goel A, Barbieri V, Costanzo F, Boland CR, Venuta S: BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer. 2003, 88: 1285-1291. 10.1038/sj.bjc.6600859.
Quinn JE, James CR, Stewart GE, Mulligan JM, White P, Chang GK, Mullan PB, Johnston PG, Wilson RH, Harkin DP: BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res. 2007, 13: 7413-7420. 10.1158/1078-0432.CCR-07-1083.
Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, Harkin DP: BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 2003, 63: 6221-6228.
Sylvain V, Lafarge S, Bignon YJ: Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line. Int J Oncol. 2002, 20: 845-853.
Ljungman M, Zhang F: Blockage of RNA polymerase as a possible trigger for uv light-induced apoptosis. Oncogene. 1996, 13: 823-831.